Clinical Trials
48 trialsTargeted Therapy Directed by Genetic Testing in Treating Patients With Locally Advanced or Advanced Solid Tumors, The ComboMATCH Screening Trial
National Cancer Institute (NCI)
A Study of the Pan-KRAS Inhibitor LY4066434 in Participants With KRAS Mutant Solid Tumors
Eli Lilly and Company
FOG-001 in Locally Advanced or Metastatic Solid Tumors
Parabilis Medicines, Inc.
Carboplatin and Paclitaxel or Oxaliplatin and Capecitabine With or Without Bevacizumab as First-Line Therapy in Treating Patients With Newly Diagnosed Stage II-IV or Recurrent Stage I Epithelial Ovarian or Fallopian Tube Cancer
National Cancer Institute (NCI)
NBTXR3, Chemotherapy, and Radiation Therapy for the Treatment of Esophageal Cancer
M.D. Anderson Cancer Center
Individual Response to Hyperthermic Intraperitoneal Chemotherapy (HIPEC) Treatment of Peritoneal Carcinomatosis From Peritoneal Mesothelioma or Atypical Mesothelial Proliferation or From Ovarian, Colorectal, or Appendiceal Histologies
National Institutes of Health Clinical Center (CC)
ARC-25
Arcus Biosciences, Inc.
QLS5132 Combination Therapy in Advanced Solid Tumors
Qilu Pharmaceutical Co., Ltd.
PIPAC for the Treatment of Peritoneal Carcinomatosis in Patients With Ovarian, Uterine, Appendiceal, Colorectal, or Gastric Cancer
City of Hope Medical Center
A Clinical Study of SHR-A1811 Combined With Chemotherapy for Platinum Sensitive Recurrent Ovarian Cancer
Suzhou Suncadia Biopharmaceuticals Co., Ltd.
COCHISE
Institut Bergonié
KEYVIBE-005
Merck Sharp & Dohme LLC
A Phase 1/2 Study of INCB001158 in Combination With Chemotherapy in Subjects With Solid Tumors
Incyte Corporation
Phase IB Study to Evaluate the Safety of Selinexor (KPT-330) in Combination With Multiple Standard Chemotherapy or Immunotherapy Agents in Patients With Advanced Malignancies
M.D. Anderson Cancer Center
SHR - A1811 Injection in the Treatment of Platinum-sensitive Recurrent Ovarian Cancer
Tongji Hospital
QUILT-3.051: NANT Ovarian Cancer Vaccine: Combination Immunotherapy in Subjects With Epithelial Ovarian Cancer Who Have Progressed on or After Standard-of-care (SoC) Therapy
ImmunityBio, Inc.
IVY
Eli Lilly and Company
PIPAC
National University Hospital, Singapore
Docetaxel, Oxaliplatin and 5-FU for Gastric Cancer With Inoperable Malignant Bowel Obstruction
Sixth Affiliated Hospital, Sun Yat-sen University
PIPAC-OPC2
Odense University Hospital
Adjuvant Pressurized IntraPeritoneal Aerosol Chemotherapy (PIPAC) in Resected High Risk Colon Cancer Patients
Odense University Hospital
Trial of Intraperitoneal (IP) Oxaliplatin in Combination With Intravenous FOLFIRI
University of Massachusetts, Worcester
COLOPEC
Academisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA)
GASPACCO
St. Petersburg State Pavlov Medical University
PI-CaP
Fondazione del Piemonte per l'Oncologia
Durvalumab and Tremelimumab in Combination With First-Line Chemotherapy in Advanced Solid Tumors
AstraZeneca
Perioperative Chemotherapy With Bevacizumab for Colorectal Carcinomatosis French Part of the Main Bev-IP Study
Hospices Civils de Lyon
PGA
Western Regional Medical Center
CatuNeo
AIO-Studien-gGmbH
Treating Peritoneal Carcinomatosis With PIPAC
Odense University Hospital
A Phase II Study of Surgical Debulking With Peritonectomy and Biweekly Intraperitoneal 5FU With Systemic Oxaliplatin/5FU/Leucovorin in Patients With Pseudomyxoma Peritonei or Peritoneal Carcinomatosis
Washington University School of Medicine
Systemic Chemotherapy With or Without Intraperitoneal Chemohyperthermia in Treating Patients Undergoing Surgery for Peritoneal Carcinomatosis From Colorectal Cancer
UNICANCER
Oxaliplatin and Topotecan in Advance Ovarian Cancer
National Cancer Institute (NCI)
Oxaliplatin and Paclitaxel in Treating Patients With Locally Recurrent or Metastatic Cervical Cancer
National Cancer Institute (NCI)
A Trial Evaluating Efficacy and Safety of Oxaliplatin With 5-Fluorouracil in Patients With Recurrent Ovarian Carcinoma
Jules Bordet Institute
Oxaliplatin and Fluorouracil in Treating Patients With Recurrent Ovarian Cancer
National Cancer Institute (NCI)
Oxaliplatin, Gemcitabine and Bevacizumab in Women With Recurrent Mullerian Carcinoma
Dana-Farber Cancer Institute
Veliparib, Oxaliplatin, and Capecitabine in Treating Patients With Advanced Solid Tumors
National Cancer Institute (NCI)
Oxaliplatin in Treating Patients With Persistent or Recurrent Endometrial Cancer
National Cancer Institute (NCI)
Oxaliplatin in Treating Patients With Recurrent or Refractory Ovarian Epithelial Cancer or Primary Peritoneal Cancer That Has Not Responded to Platinum- Based Chemotherapy
National Cancer Institute (NCI)
Oxaliplatin in Treating Patients With Recurrent or Refractory Cervical Cancer
National Cancer Institute (NCI)
Oxaliplatin in Treating Young Patients With Recurrent Solid Tumors That Have Not Responded to Previous Treatment
National Cancer Institute (NCI)
TEACO
Sanofi
Oxaliplatin With Or Without Floxuridine and Leucovorin in Treating Patients With Metastatic Cancer of the Peritoneum
National Cancer Institute (NCI)
Oxaliplatin and Topotecan in Treating Patients With Previously Treated Ovarian Epithelial, Primary Peritoneal, or Fallopian Tube Cancer
NYU Langone Health
Patients Who Have Failed First Line Treatment for Locally Advanced and/or Metastatic Cervical Cancer
Sanofi
Docetaxel and Oxaliplatin in Treating Patients With Stage III or Stage IV Ovarian Epithelial Cancer
National Cancer Institute (NCI)
Endometrial Cancer - LOHP Alone and With 5FU
Sanofi